beta-lactamase

All Gram-negative bacilli isolates which showed a diameter of inhibition zone less than 17 mm for ceftazidime, less than 19 mm for ceftriaxone and less than 22 mm for cefotaxime were selected for testing ESBL enzyme production using Double Disc Synergy Test (DDST) as previously reported.

Commercially available beta-lactamase inhibitors i.e., calvlanic acid and sulbactam or tazobactam, inhibit the ESBLs (TEM and SHV family) to some extent.7,8 Sulbactum or clavulanic acid are used as ESBL inhibitors.

A high rate of clinical failure among patients who were infected with ESBL producing bacteria and who received initial antimicrobial therapy, especially cephalosporin has been demonstrated.

The [beta]-lactamases were screened for ESBL, AmpC, and carbapenemases by double disc diffusion test with discs containing clavulanic acid (4 [micro]g/mL), boronic acid (400 [micro]g/mL) and EDTA (320 [micro]g/mL).

Second, we examined the contribution of food-origin isolates to locally disseminated ESBL E.

There are several risk factors that may contribute to the prevalence of ESBL infection among patients and healthcare workers.

Increase resistant rates and ESBL production between E.

ESBL enzymes, which are largely plasmid mediated, are capable of hydrolyzing ESCs and aztreonam, but are inhibited by clavulanic acid, tazobactam or sulbactam (5).

Carbapenem Resistance in ESBL Positive Enterobacteriaceae Isolates Causing Invasive Infections.

In Saudi Arabia, previous studies have been conducted to determine the prevalence of ESBL-producing Enterobacteriaceae (EPE), with CTX-M enzymes being the most common ESBL type [23-30].